Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irradiated Haplo-Allogeneic Cells Post-Transplant
NCT03272633Phase 1Terminated
- Sponsor
- Rutgers University
- Start
- Oct 2020
- Primary completion
- Jun 2022
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of irradiated haplo-allogeneic cells in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and 5 more (2 cohorts), sponsored by Rutgers University. Primary endpoints: Number of Participants Who Received Irradiated Haploidentical Cells (IHC) With Disease Response and Number of Participants With Toxicities Associated With Administration of Irradiated Haploidentical Cells (IHC). Started Oct 2020; status: terminated.
02
Drugs
irradiated haplo-allogeneic cells
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)mantle cell lymphoma (MCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03272633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03272633.